Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Mar 11;25(7):1424–1431. doi: 10.1016/j.bbmt.2019.03.001

Figure 3. The risk of relapse did not differ between patients who received alternative AEMs compared to those who received phenytoin after conditioning with BU followed by CY for treatment of AML, CML, MDS or lymphoid malignancies.

Figure 3.

Diamonds indicate the hazard ratio point estimates of relapse for the alternative AEM group compared to the phenytoin group. Bars indicate the 95% confidence intervals. Each statistical model included risk factor covariate adjustments derived from the entire cohort.